{"name":"Abeona Therapeutics, Inc","slug":"abeona-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"EB-101","genericName":"EB-101","slug":"eb-101","indication":"Cerebral adrenoleukodystrophy (CALD)","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ABO-101","genericName":"ABO-101","slug":"abo-101","indication":"Fanconi anemia complementation group C (FA-C)","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"MSI-78","genericName":"MSI-78","slug":"msi-78","indication":"Diabetic foot ulcers with Pseudomonas aeruginosa infection","status":"phase_3"}]}],"pipeline":[{"name":"EB-101","genericName":"EB-101","slug":"eb-101","phase":"phase_3","mechanism":"EB-101 is a gene therapy that delivers a functional copy of the ABCD1 gene to restore adrenoleukodystrophy protein function in patients with cerebral adrenoleukodystrophy.","indications":["Cerebral adrenoleukodystrophy (CALD)"],"catalyst":""},{"name":"ABO-101","genericName":"ABO-101","slug":"abo-101","phase":"phase_2","mechanism":"ABO-101 is a gene therapy that delivers a functional copy of the FANCC gene to correct Fanconi anemia complementation group C deficiency.","indications":["Fanconi anemia complementation group C (FA-C)"],"catalyst":""},{"name":"MSI-78","genericName":"MSI-78","slug":"msi-78","phase":"phase_3","mechanism":"MSI-78 is an antimicrobial peptide that disrupts bacterial cell membranes to treat infections caused by multidrug-resistant pathogens.","indications":["Diabetic foot ulcers with Pseudomonas aeruginosa infection","Multidrug-resistant gram-negative bacterial infections"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE1waUlmYm04ZWM3T1dPdWFvX2lFYnJnS2c2b1A1N2E3XzBTNXRNbzRiWlFVZFhHVUtwbGU0SUFhQzJKVkNrcDQ5T0FkSDczcUs0bFQxUDR3azM2NWZubkxnWmxYa9IBY0FVX3lxTE1waUlmYm04ZWM3T1dPdWFvX2lFYnJnS2c2b1A1N2E3XzBTNXRNbzRiWlFVZFhHVUtwbGU0SUFhQzJKVkNrcDQ5T0FkSDczcUs0bFQxUDR3azM2NWZubkxnWmxYaw?oc=5","date":"2026-04-07","type":"pipeline","source":"Bitget","summary":"Abeona Therapeutics Announces Appointment of Keith A. Goldan to its Board of Directors - Bitget","headline":"Abeona Therapeutics Announces Appointment of Keith A. Goldan to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxOdW5tS1RtcGw5aVhqa1Nubi14Y3JCSkhJRlNFdlJHSDg3Smw5eXFxY05GOHNKb0xERnR0NGpKbzFZTmV0YVRqQVpXQWl5Rm9KMDNvT3pyaTdUaThrM2t2YVFDNjBMVUZPcVVIZk1WTnpVeDMxYXUybDEyZVplZkZ6R2oxNXNVOURqeThucXQ5aWNpQXNpb3B4UWY5T1FmekFJZnR4OUNmcmJlUTF0VFBfVnlkTTBEdWxfYktFT2VYWHJab3J3SmJ4MTRSNXRsRnU4ajJJbGZZZ1NVQlNZcVNVMHN3MUs5b2J6RVhqTXh0TGswVzRTZnAzNjlvSERHY00?oc=5","date":"2026-04-07","type":"pipeline","source":"The Globe and Mail","summary":"Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors - The Globe and Mail","headline":"Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNblYwYU1ILWxmdTF5U2lFTE5oUElvSUQ2UlJLZjRFVkNMbkpVdE4yLUdXbkI3Z0FLYXkwUmVzbVpSVnZ2RVpjTFRXXzJKc0ZHOEhCSGtXOWxIRmhNX0JuS3JQcmdYV3RqNlJ2dWNNQmVwSzFhdkQ1N0RrcXhPd1NMLWd1RTRXVGNUQ1ZfcURNY3J0WHlaYXBQQzdhZ3hPekUxZmJHd0FUV0lXNXZzRW1HYWkwTmJKNFdyeXcwS2Rn?oc=5","date":"2026-04-07","type":"pipeline","source":"Stock Titan","summary":"Biotech Abeona taps veteran CFO Keith Goldan to oversee audits - Stock Titan","headline":"Biotech Abeona taps veteran CFO Keith Goldan to oversee audits","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPakt1U19LdjZlZ2JiNkZJWFBybjh0cVBiZ1Y2azVUWnNCaTNrTXBaOXFBMHFxSTZ5YmNMczhLbHYxT3lQZVQ4eDlvbXFvR3pRbUZsMFgtS0ItMi1CdEs4NnhiSW9ZX3FhaDVjeExpMFFrbGFVRE9nTHhwSVpRVnNDdUd2WGlrWUpGZk1uY29fMlVncGxkVkU1UXk4cEF4b2lUaUc4LXZubDVfNk1JeDlhMS1LbVhTakxmdXY0?oc=5","date":"2026-03-17","type":"pipeline","source":"Stock Titan","summary":"First ZEVASKYN patients treated as Abeona banks $191M cash - Stock Titan","headline":"First ZEVASKYN patients treated as Abeona banks $191M cash","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxOVkoyYXJvQTcxSmNTWjRkOGpVazBrTUd1TU1QRzJZM3JZYkV5X3ZiczRGbTg2aW00QzZDLWg2R2d2enJwczA1aklXMWVjaG1IS0tXQjRNN1MxZHZPS2lBNnIwVW85aUFFeVlWYnBZVktSczdDZFZ5aVRZc0o1cElkZ0ljdWM0THFaSG5jdk94WjhWUE1LQ3BrMXVyXy05ZHdsXy0xSVlPSURCOC1tV2s3MWwtYktRVEVqMk83RG1PVXNWM2lYa09RX3ljQ0M0Q1VTZVduVG5lSzQwYzVDRzNVcjlHTFJDeWtQZ0VJSXdMRQ?oc=5","date":"2025-12-15","type":"pipeline","source":"GlobeNewswire","summary":"Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer - GlobeNewswire","headline":"Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOX2JOdzBodVdTTjdXeThDSGdZR3YySjgxWmNURlFXU2NhUFlFdmRQUF92N3I5YlVvcEpmZm44TThMSmpRMzI1ZTFNRXhuYUNZVEoxSVRlS25JSnhtWWh3TlZZMEE3dnpJbXQwU0lITlUzODJ3RV9iWDVOOV9GNEZqNVVUMnRqMFdyZEJueUUwUWpqRWc?oc=5","date":"2025-08-30","type":"pipeline","source":"Cleveland Magazine","summary":"Abeona Therapeutics Planning Expansion in Midtown - Cleveland Magazine","headline":"Abeona Therapeutics Planning Expansion in Midtown","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNa2pCT3d4OV95NmJPX3MtWDgwUjdudWVqbkJ6cXdiNDRXaTFpcTVQX0wwX2xUZ2hIekg0SC0tenFCc1QxYXlqZzR4eUZ6RnRVcFZZZWNMR1VIbzQzMlBfYUVuQm5WZzJBN1l5ak8zRVByNGZ3RjM5cVhsNnk1d0xWUQ?oc=5","date":"2025-08-28","type":"pipeline","source":"NEOtrans","summary":"Abeona Therapeutics to expand in Midtown - NEOtrans","headline":"Abeona Therapeutics to expand in Midtown","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-18","type":"pipeline","source":"simplywall.st","summary":"Loss-Making Abeona Therapeutics Inc. (NASDAQ:ABEO) Set To Breakeven - simplywall.st","headline":"Loss-Making Abeona Therapeutics Inc. (NASDAQ:ABEO) Set To Breakeven","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPTGFlNmx0T2ZSSXpIclNPMjdnLVUxX3JkUHB1REtfbzdhcktLbkI5X3pVT0NWYXFKSGNFT1g5alRCNTlXOUs4R040V28tTXZrNXNrVzROYlFTTUtsMDQweldLYnY3cEZ2eU16ZjdkWnJmcENhaURsVTZ0MlJoYWpWd3lMdlMtR0thY3BpZEVaV3JWdFpWSm81ZjhUdnZSaEhyTDFDdjdzNF9pMC1IcmlZQjcwcWJxRTlsY2M0NHE1TUlxVDNPMDZ3RklpcjRCMHNRVnF5VzQzR3BUVWNyZF9JWUhyc210TzR6YzZjakp6cE9vRzIxOVRNWlVR?oc=5","date":"2025-05-22","type":"regulatory","source":"prnewswire.com","summary":"ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic Epidermolysis Bullosa Market | DelveInsight - prnewswire.com","headline":"ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic Epidermolysis Bullosa Market | DelveInsight","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNVzNWVnhzcllpcmFIeXYxeExWc056VGVmaTM3LS1qS0lPM1V2R0xKVDFpLWJXZFFWRWhMSXRHYWQ0VGIzdjhtRVNETWFqZ25FcWJ3aVBCcUh5RnVXTTB2WVVqYUJIdmIwYm5vV2R0Ukdxd2Y3Zno2NTBpS25INlJJMHVkTDFsUnh4TTFuRXl3RzlCc2s3dkQteDNFdElZb3JtTElzdDctWnVzSHZ6?oc=5","date":"2025-04-30","type":"regulatory","source":"Pharmaceutical Technology","summary":"FDA approves Abeona’s $3.1m cell therapy for rare skin disease - Pharmaceutical Technology","headline":"FDA approves Abeona’s $3.1m cell therapy for rare skin disease","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxON3EwSlN4U2FTZ0R1ekZ6SHRkY1kweFZPdnFvbW5fbkJLWlIxNHNfaTJfSk1yUGJJVWFGc00teXd2aHZtRHJ5YnJnMEUyX3BEcHhQWl9ZSFhVTVpqNVV6QzJabDVtdWV1MDIxMndtNzRDVmluY3h5Ukp4SHdjd0UzckdTUjQyVGVfRmtSUTBadnl4NXFwaHE3WENIQ3UyaXJyb2tudHdqVmx3ZFo4OVNuTjVpb3ZRXzBa?oc=5","date":"2025-04-29","type":"regulatory","source":"Reuters","summary":"US FDA approves first cell-based gene therapy for rare genetic skin disorder - Reuters","headline":"US FDA approves first cell-based gene therapy for rare genetic skin disorder","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQLXgzRXZMaXVGOGdOS3c0NDRXYTFLa2RydzJrUkIxM1VTOThMYy16c2hSM21JYk8xSVp1U3E5N3VOc19mM0wzU1JrMzRTVW1hdXdadlpieXhvMlV2SWM1WngwUzNadW5FVU8xNTA1aDNPVDlCRU1leTFaWTJCemRVZF9pY3hlVG5CZUE2cFItdzJsS2JpZm5ncnE5cno4NFJ2VTlOcnNMT3p6eW9qdWJBRS1SUDdqNkU4Z0llWmhuRkdrQjdrTHNB?oc=5","date":"2025-04-29","type":"regulatory","source":"Fierce Pharma","summary":"Abeona enters commercial gene therapy arena with FDA nod for Zevaskyn to treat rare genetic skin disease - Fierce Pharma","headline":"Abeona enters commercial gene therapy arena with FDA nod for Zevaskyn to treat rare genetic skin disease","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":2,"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}